Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Touchscreen Tests for Ketamine-Induced Cognitive Deficits
NCT03469089Phase 1Unknown
- Sponsor
- University of Eastern Finland
- Start
- Mar 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of modafinil in schizophrenia (4 arms), sponsored by University of Eastern Finland. Primary endpoint: Ketamine-induced cognitive deficits. Status: unknown.
02
Drugs
modafinil
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT03469089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03469089.